News
| 12/07/2011 |
Memgen Announces Upcoming Presentation for ISF35 in Chronic Lymphocytic Leukemia at 2011 American Society of Hematology Annual MeetingMemgen announces the following abstract on ISF35, the Company's lead product, will be presented during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA. |
| 06/21/2011 |
Memgen Presents Clinical Results for ISF35 in Chronic Lymphocytic Leukemia at ASCO 2011Memgen announced the presentation of clinical results for its lead product, ISF35, during the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois June 3-7, 2011. |
| 12/09/2010 |
Memgen Announces Clinical and Preclinical Results for ISF35 in Chronic Lymphocytic Leukemia and Non-Hodgkin's LymphomaMemgen announced the presentation of clinical and preclinical results for its lead product, ISF35, during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. |
| 12/08/2009 |
Memgen's ISF35 Sensitizes Cancer Cells to ChemotherapyPositive data evaluating ISF35 in combination with chemotherapy in resistant chronic lymphocytic leukemia (CLL) were presented December 7 at ASH. |
| 12/01/2009 |
Memgen's Clinical Trial Results of ISF35 for Chronic Lymphocytic Leukemia Selected for Presentation at ASH 2009 Annual MeetingResults from a recent clinical trial of ISF35 will be presented at the annual meeting of the American Society of Hematology (ASH) on December 7 in New Orleans. |
| 06/04/2009 |
ASCO Presentation Highlights Memgen's ISF35 Anti-Cancer Activity in Chronic Lymphocytic LeukemiaResults from the latest clinical trials completed with ISF35 were presented at the American Society of Clinical Oncology annual meeting on June 1 in Orlando. |
| 06/04/2009 |
Memgen Reports Positive Results for ISF35 in High-Risk Chronic Lymphocytic LeukemiaPhase Ib study of ISF35 has produced positive results, including a complete remission in the trial's first patient who had 17p deleted chronic lymphocytic leukemia (CLL). |
| 05/26/2009 |
Memgen's ISF35 Clinical Trial Featured at ASCO Annual 2009 MeetingResults from a recent clinical trial of ISF35 will be presented at the annual meeting of the American Society of Clinical Oncology June 1 in Orlando. |
| 12/03/2008 |
Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 ASH Annual MeetingMemgen's CLL clinical trials at UCSD and M.D. Anderson will be presented at ASH, Dec. 6-9 |
| 11/03/2008 |
Moores UCSD Cancer Center Studying Novel Leukemia Vaccine for High-Risk PatientsUCSD begins new Phase I clinicial trial of ISF35 in high risk CLL patients |
| 06/18/2008 |
The Leukemia & Lymphoma Society, Memgen Collaborate on CLL Clinical TrialThe Leukemia & Lymphoma Society (LLS) and Memgen collaborate on a new Phase I clinical trial for CLL. |
| 12/17/2007 |
UCSD Launches Vaccine Therapy Trial for Chronic Lymphocytic Leukemia (CLL)Patients with CLL who have failed chemotherapy or have chosen to forego it have an opportunity to participate in a clinical trial at UCSD. |